JNJ
Johnson & Johnson
JNJ's outlook is improving despite an expensive valuation.
OSCR
Oscar Health, Inc.
OSCR has the edge over JNJ overall, supported by stronger modeled upside and stronger fundamentals.
JNJ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
JNJ's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
JNJ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $114 | -60% |
| Fair | 24x | $159 | -44% |
| Forward | 25x | $284 | — |
| Expensive | 29x | $191 | -33% |
| Current | 43x | $284 | — |
Historical ranges are pointers, not guarantees.
JNJ's PE is in its expensive range at 43x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over JNJ in the historical PE scenario, which offers more potential upside but is not a forecast.
JNJ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JNJ, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over JNJ on the outlook, with more favorable profitability expectations.
JNJ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.26 | +71% |
| Q3 2026 | $6.58 | -36% |
| Q2 2026 | $8.61 | -7.9% |
| Q1 2026 | $8.63 | -4% |
| Q4 2025 | $11.03 | +91% |
| Q3 2025 | $10.36 | +71% |
| Q2 2025 | $9.35 | -38% |
| Q1 2025 | $8.99 | -41% |
| Q4 2024 | $5.79 | -58% |
JNJ's earnings per share have fallen from their peak: $6.58 over the past year, against $15.18 in early 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over JNJ on earnings, with more consistent year-over-year improvement.
JNJ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.4B | +5.9% |
| Q2 2026 | $25.3B | +6.6% |
| Q1 2026 | $24.1B | +9.9% |
| Q4 2025 | $24.6B | +9.1% |
| Q3 2025 | $24B | +6.8% |
| Q2 2025 | $23.7B | +5.8% |
| Q1 2025 | $21.9B | +2.4% |
| Q4 2024 | $22.5B | +5.3% |
JNJ's revenue has grown year over year for nine quarters in a row: $25.4B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.1% | -31 points |
| Q2 2026 | 27% | -0.7 points |
| Q1 2026 | 25% | -37 points |
| Q4 2025 | 20% | +3 points |
| Q3 2025 | 31% | +16 points |
| Q2 2025 | 27% | +1.7 points |
| Q1 2025 | 62% | +45 points |
| Q4 2024 | 17% | -5.3 points |
JNJ's operating margin was 0.1% last quarter, down 31 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over JNJ on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over JNJ on profitability, with a higher operating margin.
JNJ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.4B | -21% |
| Q2 2026 | $7.3B | +157% |
| Q1 2026 | $1.5B | -57% |
| Q4 2025 | $5.5B | +1.9% |
| Q3 2025 | $8B | +15% |
| Q2 2025 | $2.8B | -39% |
| Q1 2025 | $3.4B | +19% |
| Q4 2024 | $5.4B | -14% |
JNJ's free cash flow has been positive every quarter for seven years: $20.6B over the past year, up 5.1% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over JNJ on cash flow, with more consistent year-over-year improvement.
JNJ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +8.5M shares |
| 1 year | +0.8% | +20M shares |
| 3 years | -4% | -101M shares |
| 5 years | -8.5% | -226M shares |
| Available history | -8.8% | -236M shares |
JNJ has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.7B |
| Q2 2026 | $221M |
| Q1 2026 | $4B |
| Q4 2025 | $1.9B |
| Q3 2025 | $1.9B |
| Q2 2025 | — |
| Q1 2025 | $2.1B |
| Q4 2024 | $282M |
JNJ spent $7.9B buying back its own shares over the past year, up 83% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
JNJ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.5x | Very low |
JNJ's net debt is about 1.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over JNJ on leverage, with a lower net debt burden relative to earnings.
JNJ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 84.7 | Overbought |
JNJ's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
JNJ PE vs Healthcare Sector
| Metric | JNJ | Sector median | Relative |
|---|---|---|---|
| PE | 43x | 26x | 67% above |
| PE % | 100 | 29 | 71 pts above |
JNJ is trading at 43x earnings, a 67% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over JNJ on valuation relative to its sector.
JNJ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $267.6 | 5.9% above |
| 20 week MA | $265.1 | 6.9% above |
| 50 week MA | $243.5 | 16% above |
| 100 week MA | $204.7 | 39% above |
| 200 week MA | $181.3 | 56% above |
JNJ is in an uptrend: it's above all five of its weekly moving averages, and 56% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
JNJ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.8 | $152.5 | +4.6% |
| 2021 | $152.5 | $168.3 | +10% |
| 2022 | $168.3 | $177.5 | +5.5% |
| 2023 | $177.5 | $156.7 | -12% |
| 2024 | $156.7 | $145.1 | -7.5% |
| 2025 | $145.1 | $207.6 | +43% |
| 2026 YTD | $207.6 | $283.5 | +37% |
JNJ has finished higher in four of the last six years. It's up 37% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over JNJ on returns for 2026, with the stronger performance.